LOS ANGELES, March 7 (Reuters) - Keryx Biopharmaceuticals Inc (KERX.O) said on Friday that a Phase 3 clinical trial for Sulonex, a drug designed to treat diabetic neuropathy, has failed to meet the study's primary objectives.
The company said it plans to re-focus its primary efforts and resources on rapidly moving renal disease drug Zerenex and cancer drug Perifosine forward. (Reporting by Gina Keating; editing by Carol Bishopric)
ISLAMABAD (Reuters) - A suicide bomber killed up to 10 people in Pakistan Friday, while a suspected U.S. drone killed six militants, as rising political tension threatened to distract the government from its war against the Taliban.
President Barack Obama met world leaders in Copenhagen in a bid to reach a new global climate agreement after all-night talks failed. Full Article | Video
Citigroup's plan to extract itself from the government's clutches didn't go as planned. For the bank to succeed, one of two things need to happen. Full Article
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
